Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3744 results
Critical Outcome Technologies receives orphan drug designation for COTI-2
Critical Outcome Technologies has announced that the US Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer.
Drug Research > Drug Discovery & Development > News
Boehringer Ingelheim, Lilly announce resubmission of new drug application to FDA for empagliflozin
Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company have announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the US Food and Drug Administration (FDA).
Drug Research > Drug Discovery & Development > News
TG Therapeutics releases preliminary clinical results from Phase II study of TG-1101
TG Therapeutics has announced preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA(TM)), the oral BTK inhibitor from Pharmacyclics/Janssen.
Drug Research > Drug Discovery & Development > News
Sanofi, Medtronic to form strategic alliance in diabetes
Sanofi and Medtronic have signed a memorandum of understanding to enter into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world.
Drug Research > Drug Discovery & Development > News
Janssen, ViiV Healthcare to develop two-drug single tablet regimen for HIV-1
By PBR Staff Writer
Janssen R&D Ireland and ViiV Healthcare have entered into a collaboration to develop and commercialize a new single tablet regimen containing Janssen's rilpivirine and ViiV's dolutegravir as the sole active ingredients for maintenance treatment of people with human immunodeficiency virus (HIV).
Drug Research > Drug Discovery & Development > News
MorphoSys, Merck Serono to develop new therapeutic antibodies
By PBR Staff Writer
MorphoSys and Merck have signed co-development and license agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints.
Drug Research > Drug Discovery & Development > News
Endonovo to develop next generation cell free regenerative products
Endonovo Therapeutics, a biotechnology company developing innovative regenerative therapies, has announced that it has created technologies to pursue the development and manufacturing of next generation regenerative products that no longer require the administration of stem cells.
Drug Research > Drug Discovery & Development > News
Agios starts multiple ascending dose Phase I trial of AG-348 to treat PK deficiency
By PBR Staff Writer
Agios Pharmaceuticals has started a multiple ascending dose (MAD) Phase I trial of AG-348 in healthy volunteers for the treatment of pyruvate kinase (PK) deficiency, a rare, hemolytic anemia.
Drug Research > Drug Discovery & Development > News
ScinoPharm to provide API to TaiGen for new stem cell drug
ScinoPharm Taiwan, specializing in the development and manufacture of active pharmaceutical ingredients, and TaiGen Biotechnology have signed a manufacturing contract for the clinical supply of the API of Burixafor, a new chemical entity discovered and developed by TaiGen.
Drug Research > Drug Discovery & Development > News
ArGEN-X, Shire Pharma enter long-term strategic alliance for new therapeutic antibodies
By PBR Staff Writer
arGEN-X, a Dutch biopharmaceutical firm focused on developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, has entered into a long-term strategic alliance with Shire Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Trevi Therapeutics gets $25m series B financing for development of nalbuphine ER
Trevi Therapeutics, a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, has announced a Series B financing of $25m led by TPG Biotech, the life science venture investment arm of TPG, with $15m funded at first closing.
Drug Research > Drug Discovery & Development > News
Asana acquires branded drug discovery platform from Endo Pharmaceuticals
By PBR Staff Writer
Asana BioSciences, a US-based research and development firm specializing in the discovery and development of new chemical and biological entities, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International.
Drug Research > Drug Discovery & Development > News
Genmab, GSK to start studies of subcutaneous ofatumumab for RRMS and NMO
By PBR Staff Writer
Denmark-based Genmab has announced that its collaboration partner GlaxoSmithKline (GSK) has taken the decision to start additional pivotal studies with the subcutaneous formulation of ofatumumab.
Drug Research > Drug Discovery & Development > News
Benitec commences patient dosing with TT-034 in patients with hepatitis C
Benitec Biopharma has dosed the first patient in its 'first in man', Phase I/IIa clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection.
Drug Research > Drug Discovery & Development > News
Rodin secures $12.9m Series A financing to develop novel treatments for CNS disorders
Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, has closed a $12.9m Series A financing round.
Drug Research > Drug Discovery & Development > News
61-75 of 3744 results